Physician profile
Paul Bell
NPI 1386034627
$4,097.20
in general payments reported to CMS, 2019-2025
18 companies · $697 in 2025
The $697 reported for 2025 was more than what 90% of Aerospace Medicine providers received nationally (typical 2025 total: $89.75).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $139 · 2021: $364 · 2022: $915 · 2023: $1,274 · 2024: $708 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $933.16 | 2021-2025 | Clareon, Clareon Panoptix Pro |
| Sun Pharmaceutical Industries INC. | $530.28 | 2023-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $475.58 | 2021-2025 | Tecnis Iol, Veritas Vision System |
| Glaukos Corporation | $433.02 | 2021-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $375.87 | 2022-2025 | Victus, Envista Mx60 Iol, Stellaris |
| Biotissue Holdings INC. | $371.13 | 2020-2025 | |
| Abbvie INC. | $170.73 | 2023-2025 | Xen Glaucoma Treatment System |
| Mallinckrodt Hospital Products INC. | $149.45 | 2021-2025 | Acthar |
| Allergan, INC. | $118.13 | 2020 | |
| Horizon Therapeutics Plc | $113.27 | 2022 | |
| Genentech USA, INC. | $109.65 | 2023 | Vabysmo |
| New World Medical,INC. | $100.32 | 2024 | Streamline, Ahmed Glaucoma Valve, Clearpath |
| Novartis Pharmaceuticals Corporation | $67.52 | 2021 | |
| Harrow Eye, LLC | $46.90 | 2023-2025 | Vevye, Iheezo |
| Oyster Point Pharma, INC. | $40.98 | 2023-2025 | Tyrvaya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $27.29 | 2025 | Oxervate |
| Merck Sharp & Dohme LLC | $17.52 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.